Sanofi SA (SNY)
47.98
+0.20
(+0.42%)
USD |
NASDAQ |
Nov 21, 16:00
47.98
0.00 (0.00%)
After-Hours: 20:00
Sanofi Enterprise Value: 136.14B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 136.14B |
| November 19, 2024 | 136.69B |
| November 18, 2024 | 137.97B |
| November 15, 2024 | 136.62B |
| November 14, 2024 | 136.24B |
| November 13, 2024 | 140.48B |
| November 12, 2024 | 142.06B |
| November 11, 2024 | 143.26B |
| November 08, 2024 | 145.02B |
| November 07, 2024 | 146.04B |
| November 06, 2024 | 144.86B |
| November 05, 2024 | 148.85B |
| November 04, 2024 | 149.10B |
| November 01, 2024 | 149.90B |
| October 31, 2024 | 148.93B |
| October 30, 2024 | 150.36B |
| October 29, 2024 | 151.31B |
| October 28, 2024 | 152.64B |
| October 25, 2024 | 152.59B |
| October 24, 2024 | 146.85B |
| October 23, 2024 | 148.95B |
| October 22, 2024 | 149.88B |
| October 21, 2024 | 150.88B |
| October 18, 2024 | 154.07B |
| October 17, 2024 | 153.89B |
| Date | Value |
|---|---|
| October 16, 2024 | 152.84B |
| October 15, 2024 | 153.16B |
| October 14, 2024 | 154.04B |
| October 11, 2024 | 154.14B |
| October 10, 2024 | 153.66B |
| October 09, 2024 | 154.62B |
| October 08, 2024 | 153.87B |
| October 07, 2024 | 153.64B |
| October 04, 2024 | 155.42B |
| October 03, 2024 | 155.60B |
| October 02, 2024 | 157.38B |
| October 01, 2024 | 160.03B |
| September 30, 2024 | 160.84B |
| September 27, 2024 | 160.87B |
| September 26, 2024 | 159.24B |
| September 25, 2024 | 158.36B |
| September 24, 2024 | 160.79B |
| September 23, 2024 | 160.32B |
| September 20, 2024 | 160.82B |
| September 19, 2024 | 162.40B |
| September 18, 2024 | 160.42B |
| September 17, 2024 | 159.01B |
| September 16, 2024 | 160.07B |
| September 13, 2024 | 159.56B |
| September 12, 2024 | 158.61B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
106.37B
Minimum
Sep 27 2022
163.07B
Maximum
Sep 04 2024
136.52B
Average
137.42B
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 221.25B |
| GSK PLC | 84.49B |
| Eli Lilly and Co | 742.91B |
| Novavax Inc | 550.83M |
| Regeneron Pharmaceuticals Inc | 73.87B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.096B |
| Revenue (Quarterly) | 15.57B |
| Total Expenses (Quarterly) | 11.07B |
| EPS Diluted (Quarterly) | 1.237 |
| Gross Profit Margin (Quarterly) | 71.14% |
| Profit Margin (Quarterly) | 19.88% |
| Earnings Yield | 4.11% |
| Operating Earnings Yield | 9.56% |
| Normalized Earnings Yield | 6.677 |